General Characteristics and Cytotoxic Effects of Nano-Poly (Butyl Cyanoacrylate) Containing Carboplatin on Ovarian Cancer Cells

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 Feb 28

PMID 28240014

Citations 5

Authors

Leila Kanaani

Meysam Ebrahimi far

S Maryam Kazemi

Edris Choupani

Maral Mazloumi Tabrizi

Hasan Ebrahimi Shahmabadi

Azim Akbarzadeh Khiyavi

Affiliations

Soon will be listed here.

Abstract

The initial response to treatment and subsequent development of resistance to carboplatin are very important challenges. Use of nano drug delivery is a new method to replace standard chemotherapy. In this research, both non-PEGylated and PEGylated nanoparticles (NPs) were prepared by mini-emulsion polymerization of poly (butyl cyanoacrylate) (PBCA) NPs. Characteristics such as size, polydispersity index (PDI), zeta potential, drug release, and stability were examined. In addition, infrared spectroscopy was used for description of the produced NPs. Then, cytotoxicity effects of both formulations were studied on the A2780CIS ovarian cancer cell line with incubation for 24, 48, and 72h. Examination of characteristics of loaded carboplatin on the PBCA NPs under suitable laboratory conditions showed a positive effect of PEG on their properties. Cytotoxicity studies demonstrated greater toxicity with both formulations of nano-drugs than the free drug. The results indicated that PBCA NPs can be considered as suitable candidates for nano-drugs in chemotherapy.

Citing Articles

Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.

Gralewska P, Gajek A, Marczak A, Rogalska A Int J Mol Sci. 2024; 25(15).

PMID: 39125873 PMC: 11312858. DOI: 10.3390/ijms25158304.

Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.

Hamed A, Ghareeb D, Mohamed T, Hamed M, Nofal M, Gaber M BMC Complement Med Ther. 2023; 23(1):384.

PMID: 37891562 PMC: 10604858. DOI: 10.1186/s12906-023-04212-4.

Smart Polymeric Nanoparticles in Cancer Immunotherapy.

Yu Z, Shen X, Yu H, Tu H, Chittasupho C, Zhao Y Pharmaceutics. 2023; 15(3).

PMID: 36986636 PMC: 10056399. DOI: 10.3390/pharmaceutics15030775.

Anticancer Effect of Cisplatin-Loaded Poly (Butylcyanoacrylate) Nanoparticles on A172 Brain Cancer Cells Line.

Chiani M, Toofani Milani A, Nemati M, Rezaeidian J, Ehsanbakhsh H, Ahmadi Z Asian Pac J Cancer Prev. 2019; 20(1):303-309.

PMID: 30678454 PMC: 6485583. DOI: 10.31557/APJCP.2019.20.1.303.

The Sources of Essential Fatty Acids for Allergic and Cancer Patients; a Connection with Insight into Mammalian Target of Rapamycin: A Narrative Review.

Arshad Z, Rezapour-Firouzi S, Mohammadian M, Ebrahimifar Asian Pac J Cancer Prev. 2018; 19(9):2391-2401.

PMID: 30255691 PMC: 6249470. DOI: 10.22034/APJCP.2018.19.9.2391.

References

Shahbazian S, Akbarzadeh A, Torabi S, Omidi M . Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D. Biotechnol Lett. 2015; 37(7):1355-9. DOI: 10.1007/s10529-015-1813-5. View

Behan N, Birkinshaw C, Clarke N . Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials. 2001; 22(11):1335-44. DOI: 10.1016/s0142-9612(00)00286-6. View

Fontes G, Amaral P, Nele M, Coelho M . Factorial design to optimize biosurfactant production by Yarrowia lipolytica. J Biomed Biotechnol. 2010; 2010:821306. PMC: 2846354. DOI: 10.1155/2010/821306. View

Savrikar S, Lagad C . Study of Preparation and Standardization of 'Maadhutailika Basti' with special reference to Emulsion Stability. Ayu. 2011; 31(1):1-6. PMC: 3215309. DOI: 10.4103/0974-8520.68190. View

Zarei M, Norouzian D, Honarvar B, Mohammadi M, Shamabadi H, Akbarzadeh A . Paclitaxel loaded niosome nanoparticle formulation prepared via reverse phase evaporation method: an in vitro evaluation. Pak J Biol Sci. 2014; 16(6):295-8. DOI: 10.3923/pjbs.2013.295.298. View

Knox R, Friedlos F, Lydall D, Roberts J . Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986; 46(4 Pt 2):1972-9. View

Otsuka H, Nagasaki Y, Kataoka K . PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003; 55(3):403-19. DOI: 10.1016/s0169-409x(02)00226-0. View

Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R . Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release. 2003; 91(1-2):167-72. DOI: 10.1016/s0168-3659(03)00241-4. View

Kim J, Chung H, Jeong M, Song M, Kang K, Kim J . One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. Int J Nanomedicine. 2013; 8:2247-57. PMC: 3693817. DOI: 10.2147/IJN.S45059. View

10.

Wu M, Dellacherie E, Durand A, Marie E . Poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion polymerization (1): dextran-based surfactants. Colloids Surf B Biointerfaces. 2009; 69(1):141-6. DOI: 10.1016/j.colsurfb.2008.12.010. View

11.

Zhang J, Kan Y, Tian Y, Wang Z, Zhang J . Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells. Indian J Med Res. 2013; 137(3):527-32. PMC: 3705661. View

12.

Andrieux K, Couvreur P . Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 1(5):463-74. DOI: 10.1002/wnan.5. View